Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 11/20 | 0.65 |
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.65 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.65 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.43 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.43 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.43 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.43 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.43 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL7265590 | 0.97 | SLC6A4 (0.60) | SLC6A4SLC6A3SLC6A2PSEN1PSEN2 | |
| Ammonia Solution, Strong SCHEMBL7265596 | 0.97 | SLC6A4 (0.60) | SLC6A4SLC6A3SLC6A2PSEN1PSEN2 | |
| SCHEMBL23997040 | 0.91 | SLC6A4 (0.53) | SLC6A4SLC6A3SLC6A2PSEN1PSEN2 | |
| SCHEMBL3517422 | 0.83 | SLC6A3 (0.67) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL14417007 | 0.82 | SLC6A4 (0.47) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL32670426 | 0.81 | SLC6A4 (0.55) | SLC6A4SLC6A3SLC6A2KDM1A | |
| SCHEMBL7196726 | 0.81 | SLC6A3 (0.64) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL12000523 | 0.80 | SLC6A4 (0.66) | SLC6A4SLC6A3SLC6A2PSEN1PSEN2 | |
| SCHEMBL17761207 | 0.80 | SLC6A4 (0.57) | SLC6A4SLC6A3SLC6A2PSEN1PSEN2 | |
| Water SCHEMBL7265593 | 0.79 | SLC6A3 (0.62) | SLC6A4SLC6A3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2595969-B1 | Substituted 3-phenyl-1,2,4-oxadiazole compounds | BRISTOL MYERS SQUIBB CO (US) | 2015-04-22 | — | — | EP | disclosed |
| EP-2595969-B1 | Substituted 3-phenyl-1,2,4-oxadiazole compounds | BRISTOL MYERS SQUIBB CO (US) | 2015-04-22 | — | — | EP | disclosed |
| CN-103124727-B | Substituted 3-phenyl-1,2,4-oxadiazole compounds | BRISTOL MYERS SQUIBB CO | 2015-03-25 | — | — | CN | disclosed |
| US-8822510-B2 | Substituted 3-phenyl-1,2,4-Oxadiazole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822510-B2 | Substituted 3-phenyl-1,2,4-Oxadiazole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822510-B2 | Substituted 3-phenyl-1,2,4-Oxadiazole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-02 | — | — | US | disclosed |
| US-20130158001-A1 | SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS | BRISTOL-MYERS SQUBIB COMPANY | 2013-06-20 | — | — | US | disclosed |
| US-20130158001-A1 | SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS | BRISTOL-MYERS SQUBIB COMPANY | 2013-06-20 | — | — | US | disclosed |
| US-20130158001-A1 | SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS | BRISTOL-MYERS SQUBIB COMPANY | 2013-06-20 | — | — | US | disclosed |
| EP-2595969-A1 | SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS | Bristol-Myers Squibb Company (US) | 2013-05-29 | — | — | EP | disclosed |
| CN-103124727-A | Substituted 3-phenyl-1,2,4-oxadiazole compounds | BRISTOL MYERS SQUIBB CO | 2013-05-29 | — | — | CN | disclosed |
| WO-2012012477-A1 | SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-26 | — | — | WO | disclosed |
| WO-2012012477-A1 | SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158001-A1 | SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS | S1PR1, S1PR3, S1PR2 | SLC6A4 2698/4885SLC6A3 2766/4885SLC6A2 2889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.